Transmissibility of SARS-CoV-2 among fully vaccinated individuals.
作者信息
Franco-Paredes Carlos
机构信息
Division of Infectious Diseases, University of Colorado, Anschutz Medical Center, Aurora, CO 80045, USA; Hospital Infantil de México, Federico Gómez, Mexico City, Mexico.
出版信息
Lancet Infect Dis. 2022 Jan;22(1):16. doi: 10.1016/S1473-3099(21)00768-4.
Abstract
摘要
相似文献
1
Transmissibility of SARS-CoV-2 among fully vaccinated individuals.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在完全接种疫苗个体中的传播性。
Lancet Infect Dis. 2022 Jan;22(1):16. doi: 10.1016/S1473-3099(21)00768-4.
2
Transmissibility of SARS-CoV-2 among fully vaccinated individuals.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在完全接种疫苗个体中的传播性。
Lancet Infect Dis. 2022 Jan;22(1):16-17. doi: 10.1016/S1473-3099(21)00763-5.
3
Transmissibility of SARS-CoV-2 among fully vaccinated individuals.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在完全接种疫苗个体中的传播性。
Lancet Infect Dis. 2022 Jan;22(1):17-18. doi: 10.1016/S1473-3099(21)00765-9.
4
Transmissibility of SARS-CoV-2 among fully vaccinated individuals - Authors' reply.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在完全接种疫苗个体中的传播性——作者回复
Lancet Infect Dis. 2022 Jan;22(1):18-19. doi: 10.1016/S1473-3099(21)00761-1.
5
Transmission of SARS-CoV-2 variant B.1.1.7 among vaccinated health care workers.接种疫苗的医护人员中 SARS-CoV-2 变异株 B.1.1.7 的传播。
Infect Dis (Lond). 2021 Nov;53(11):876-879. doi: 10.1080/23744235.2021.1945139. Epub 2021 Jun 26.
6
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.未接种疫苗和接种疫苗的个体中感染原始、Delta 或奥密克戎 SARS-CoV-2 的传染性病毒载量。
Nat Med. 2022 Jul;28(7):1491-1500. doi: 10.1038/s41591-022-01816-0. Epub 2022 Apr 8.
7
Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals.接种疫苗和未接种疫苗个体中的 SARS-CoV-2 传播和传染性脱落动力学。
JAMA Netw Open. 2022 May 2;5(5):e2213606. doi: 10.1001/jamanetworkopen.2022.13606.
8
Actions and attitudes on the immunized patients against SARS-CoV-2.针对 SARS-CoV-2 免疫患者的行动和态度。
Rev Esp Quimioter. 2022 Feb;35(1):7-15. doi: 10.37201/req/131.2021. Epub 2021 Oct 21.
9
Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA in Blood of Patients With Coronavirus Disease 2019 (COVID-19): What Does It Mean?2019冠状病毒病（COVID-19）患者血液中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）RNA的检测：这意味着什么？
Clin Infect Dis. 2021 Nov 2;73(9):e2898-e2900. doi: 10.1093/cid/ciaa1316.
10
SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.2021 年 5 月 1 日至 7 月 25 日，加利福尼亚州洛杉矶县≥16 岁人群中，根据疫苗接种状况划分的 SARS-CoV-2 感染和住院情况。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176. doi: 10.15585/mmwr.mm7034e5.
引用本文的文献
1
Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.基于下一代腺病毒载体的严重急性呼吸综合征冠状病毒2疫苗
Vaccines (Basel). 2025 Apr 14;13(4):406. doi: 10.3390/vaccines13040406.
2
Policy brief: Improving national vaccination decision-making through data.政策简报：通过数据改善国家疫苗接种决策
Front Public Health. 2024 Dec 17;12:1407841. doi: 10.3389/fpubh.2024.1407841. eCollection 2024.
3
Antiseptics: An expeditious third force in the prevention and management of coronavirus diseases.防腐剂：预防和管理冠状病毒疾病的一支快速起效的第三种力量。
Curr Res Microb Sci. 2024 Oct 16;7:100293. doi: 10.1016/j.crmicr.2024.100293. eCollection 2024.
4
Bacterial and Viral Co-Infections in COVID-19 Patients: Etiology and Clinical Impact.新冠病毒感染患者的细菌和病毒合并感染：病因及临床影响
Biomedicines. 2024 Sep 27;12(10):2210. doi: 10.3390/biomedicines12102210.
5
A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models.一种自我扩增的 RNA 疫苗可预防肠道病毒 D68 感染和疾病的临床前模型。
Sci Transl Med. 2024 Aug 7;16(759):eadi1625. doi: 10.1126/scitranslmed.adi1625.
6
Reduced IFNL1 and/or IFNL2, but not IFNL3 is associated with worse outcome in patients with COVID-19.IFNL1 和/或 IFNL2 减少与 COVID-19 患者的不良结局相关，但 IFNL3 则不然。
Clin Exp Immunol. 2024 Nov 12;218(3):300-307. doi: 10.1093/cei/uxae047.
7
An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission.经鼻内接种减毒的 SARS-CoV-2 疫苗可限制病毒传播。
Nat Commun. 2024 Feb 2;15(1):995. doi: 10.1038/s41467-024-45348-2.
8
A Flexible Regression Modeling Approach Applied to Observational Laboratory Virological Data Suggests That SARS-CoV-2 Load in Upper Respiratory Tract Samples Changes with COVID-19 Epidemiology.一种应用于观察性实验室病毒学数据的灵活回归建模方法表明，上呼吸道样本中的 SARS-CoV-2 载量随 COVID-19 流行病学而变化。
Viruses. 2023 Sep 23;15(10):1988. doi: 10.3390/v15101988.
9
Can a brief session of the online coronavirus disease 2019 destigmatization program reduce stigma among survivors? A randomized controlled trial.2019年冠状病毒病在线消除污名化项目的简短课程能否减少幸存者的污名化现象？一项随机对照试验。
Front Psychiatry. 2023 Aug 23;14:1234038. doi: 10.3389/fpsyt.2023.1234038. eCollection 2023.
10
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study.重组腺病毒 26 型和 5 型载体异源初免-加强 COVID-19 疫苗在健康青少年中的安全性和免疫原性：一项开放标签、非随机、多中心、1/2 期、剂量递增的研究。
Front Immunol. 2023 Aug 1;14:1228461. doi: 10.3389/fimmu.2023.1228461. eCollection 2023.
本文引用的文献
1
Viral Load Among Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Persons Infected With the SARS-CoV-2 Delta Variant.接种疫苗和未接种疫苗、无症状和有症状的感染新冠病毒德尔塔变异株者的病毒载量
Open Forum Infect Dis. 2022 Mar 17;9(5):ofac135. doi: 10.1093/ofid/ofac135. eCollection 2022 May.
2
What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?在新冠病毒德尔塔变异株的背景下，疫苗对减少传播有什么效果？
Lancet Infect Dis. 2022 Feb;22(2):152-153. doi: 10.1016/S1473-3099(21)00690-3. Epub 2021 Oct 29.
3
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.英国未接种和接种疫苗人群中 SARS-CoV-2 德尔塔（B.1.617.2）变异株的社区传播和病毒载量动力学：一项前瞻性、纵向、队列研究。
Lancet Infect Dis. 2022 Feb;22(2):183-195. doi: 10.1016/S1473-3099(21)00648-4. Epub 2021 Oct 29.
4
Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison - Texas, July-August 2021.2021 年 7 月至 8 月，德克萨斯州一联邦监狱中被监禁人员感染 SARS-CoV-2 B.1.617.2（Delta）变异株疫情。
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1349-1354. doi: 10.15585/mmwr.mm7038e3.
5
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.Covid-19 疫苗在门诊和住院治疗环境中的有效性。
N Engl J Med. 2021 Oct 7;385(15):1355-1371. doi: 10.1056/NEJMoa2110362. Epub 2021 Sep 8.
6
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.新冠疫苗突破性感染在已接种疫苗的医护人员中发生。
N Engl J Med. 2021 Oct 14;385(16):1474-1484. doi: 10.1056/NEJMoa2109072. Epub 2021 Jul 28.
Zotero 插件